CRDL Jul 2024 2.500 call
| Previous Close | 0.1500 |
| Open | 0.0900 |
| Bid | 0.0500 |
| Ask | 0.1000 |
| Strike | 2.50 |
| Expire Date | 2024-07-19 |
| Day's Range | 0.0900 - 0.1500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 2.13k |
- Baystreet
Stocks in play: Cardiol Therapeutics Inc.
Added another feather to its cap last week with the announcement of its Phase II MAvERIC-Pilot study ...
- ACCESSWIRE
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
NAPLES, FL / ACCESSWIRE / June 17, 2024 / In a phenomenal year marked by over +180% gains in its stock price, Cardiol Therapeutics Inc. (NASDAQ:CRDL)(TSX:CRDL) added another feather to its cap last week with the announcement of its Phase II MAvERIC-Pilot ...
NewsfileCardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx™ also shown to reduce inflammation in patients with elevated CRP89% of patients have continued into the extension phase of the studyToronto, Ontario--(Newsfile Corp. - June 13, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and a
